


U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Carfilzomib. [Updated 2020 Sep 21]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Carfilzomib

Revised: September 21, 2020.

CASRN: 868540-17-4



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of carfilzomib during breastfeeding. Because carfilzomib is 97% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during carfilzomib therapy and for 2 weeks after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Carfilzomib

CAS Registry Number

868540-17-4

Drug Class

Breast Feeding Lactation Antineoplastic Agents Enzyme Inhibitors Protein Kinase Inhibitors Signal Transduction Inhibitors